Stock Market News2 days Denali Therapeutics’ ALS study fails to meet primary endpoint; shares fall 19% postmarket Investing.com
Denali Therapeutics’ ALS study fails to meet primary endpoint; shares fall 19% postmarket.
XDenali Therapeutics’ ALS study fails to meet primary endpoint; shares fall 19% postmarket.
X